AR123962A1 - Inhibidores de interleucina-17 - Google Patents
Inhibidores de interleucina-17Info
- Publication number
- AR123962A1 AR123962A1 ARP210103016A ARP210103016A AR123962A1 AR 123962 A1 AR123962 A1 AR 123962A1 AR P210103016 A ARP210103016 A AR P210103016A AR P210103016 A ARP210103016 A AR P210103016A AR 123962 A1 AR123962 A1 AR 123962A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- substituted
- unsubstituted
- cycloalkyl
- phenyl
- Prior art date
Links
- 102000013691 Interleukin-17 Human genes 0.000 title abstract 4
- 108050003558 Interleukin-17 Proteins 0.000 title abstract 4
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 9
- 229910052739 hydrogen Inorganic materials 0.000 abstract 5
- 125000003709 fluoroalkyl group Chemical group 0.000 abstract 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 4
- 125000006163 5-membered heteroaryl group Chemical group 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 125000005843 halogen group Chemical group 0.000 abstract 3
- 125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 125000001153 fluoro group Chemical group F* 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 125000002950 monocyclic group Chemical group 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 2
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 abstract 1
- 125000006555 (C3-C5) cycloalkyl group Chemical group 0.000 abstract 1
- -1 N-pyridyl Chemical group 0.000 abstract 1
- 150000003869 acetamides Chemical class 0.000 abstract 1
- 150000001602 bicycloalkyls Chemical group 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 125000003566 oxetanyl group Chemical group 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- ILVXOBCQQYKLDS-UHFFFAOYSA-N pyridine N-oxide Chemical group [O-][N+]1=CC=CC=C1 ILVXOBCQQYKLDS-UHFFFAOYSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invención se refiere a nuevos compuestos de 2-formamido (N-fenil y N-piridil) acetamida sustituidos con N-óxidos de piridina que son inhibidores de interleucina-17 (IL-17), a procesos para su preparación, composiciones farmacéuticas, y medicamentos que los contienen, y a su uso en enfermedades y trastornos mediados por IL-17. Reivindicación 1: Un compuesto de la fórmula [1] en donde, R¹ es un compuesto de fórmula [2] ó [3] en donde, R⁶ en cada ocurrencia se selecciona entre H, F, Cl, alquilo C₁₋₃ y fluoroalquilo C₁₋₃; R⁷ en cada ocurrencia se selecciona entre H, F, Cl, alquilo C₁₋₃ y fluoroalquilo C₁₋₃; R⁸ se selecciona entre H, halo, alquilo C₁₋₃ e hidroximetilo; X es C o N y cuando X es N, R³ está ausente; R² se selecciona entre H y F; R³ se selecciona entre H, F y Cl; R⁴ se selecciona entre H y F; R⁵ es un heteroarilo de 5 miembros que comprende 1 ó 2 heteroátomos independientemente seleccionados entre N, S, y O, y en donde dicho heteroarilo es insustituido o sustituido con uno o dos grupos independientemente seleccionados entre alquilo C₁₋₃ y cicloalquilo C₃₋₄, en donde dicho alquilo C₁₋₃ es insustituido o sustituido con uno o más grupos independientemente seleccionados entre F, OH, alcoxi C₁₋₃, -C(O)OH y NR¹ᵇR¹ᶜ, en donde R¹ᵇ y R¹ᶜ son independientemente seleccionados entre H y alquilo C₁₋₃; o R⁵ es un heteroarilo de 5 miembros que comprende un átomo de N en donde dicho heteroarilo de 5 miembros se fusiona a un heterociclo de 6 miembros que comprende un átomo de N en donde dicho heterociclo es insustituido o sustituido con un grupo seleccionado entre alquilo C₁₋₃, alcoxi C₁₋₃ alquilo C₁₋₃, -C(O)alquilo C₁₋₃, cicloalquilo C₃₋₄ y oxetanilo; Z es un resto de fórmula [4], en donde R⁹ se selecciona entre (1) cicloalquilo C₅₋₈ monocíclico y bicicloalquilo C₆, cada uno de los cuales es independientemente insustituido o sustituido con uno o más grupos independientemente seleccionados en cada ocurrencia entre fluoro, alquilo C₁₋₃ y fluoroalquilo C₁₋₃, y en donde dicho cicloalquilo C₅₋₈ monocíclico está opcionalmente fusionado a fenilo; en donde dicho fenilo es insustituido o sustituido con uno o más grupos seleccionados entre halo, alquilo C₁₋₃, cicloalquilo C₃₋₅ o fluoroalquilo C₁₋₃; (2) cicloalquenilo C₅₋₈ monocíclico, que es insustituido o sustituido con uno o más fluoro; (3) alquilo C₁₋₃, que es insustituido o sustituido con uno o dos grupos fenilo, en donde dicho fenilo en cada ocurrencia es independientemente insustituido o sustituido con uno o más halo; o una sal farmacéuticamente aceptable del mismo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20205121 | 2020-11-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR123962A1 true AR123962A1 (es) | 2023-01-25 |
Family
ID=73059405
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210103016A AR123962A1 (es) | 2020-11-02 | 2021-10-29 | Inhibidores de interleucina-17 |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20230391782A1 (es) |
| EP (1) | EP4237417A1 (es) |
| JP (1) | JP2023547470A (es) |
| KR (1) | KR20230091945A (es) |
| CN (1) | CN116323596A (es) |
| AR (1) | AR123962A1 (es) |
| AU (1) | AU2021368247B2 (es) |
| CA (1) | CA3190738A1 (es) |
| CL (1) | CL2023001220A1 (es) |
| CO (1) | CO2023005280A2 (es) |
| CR (1) | CR20230180A (es) |
| DO (1) | DOP2023000081A (es) |
| EC (1) | ECSP23030375A (es) |
| IL (1) | IL302447A (es) |
| MX (1) | MX2023005076A (es) |
| PE (1) | PE20231047A1 (es) |
| TW (1) | TW202227408A (es) |
| UY (1) | UY39484A (es) |
| WO (1) | WO2022091056A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023025783A1 (en) | 2021-08-23 | 2023-03-02 | Leo Pharma A/S | Small molecule modulators of il-17 |
| WO2023111181A1 (en) | 2021-12-16 | 2023-06-22 | Leo Pharma A/S | Small molecule modulators of il-17 |
| WO2023166172A1 (en) | 2022-03-04 | 2023-09-07 | Leo Pharma A/S | Small molecule modulators of il-17 |
| WO2024115662A1 (en) | 2022-12-02 | 2024-06-06 | Leo Pharma A/S | Small molecule modulators of il-17 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6562333B1 (en) | 1993-06-14 | 2003-05-13 | Schering Corporation | Purified mammalian CTLA-8 antigens and related reagents |
| US20050070567A1 (en) | 2002-08-12 | 2005-03-31 | The Regents Of The University Of Michigan | Diagnosis and treatment of diseases arising from defects in the tuberous sclerosis pathway |
| GB0417487D0 (en) | 2004-08-05 | 2004-09-08 | Novartis Ag | Organic compound |
| JP6347949B2 (ja) | 2010-04-26 | 2018-06-27 | ノバルティス アーゲー | 改良型細胞培養培地 |
| WO2013116682A1 (en) | 2012-02-02 | 2013-08-08 | Ensemble Therapeutics Corporation | Macrocyclic compounds for modulating il-17 |
| US20150252028A1 (en) | 2012-10-24 | 2015-09-10 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| WO2014066726A2 (en) | 2012-10-26 | 2014-05-01 | Ensemble Therapeutics Corporation | Compounds for modulating il-17 |
| KR101877109B1 (ko) | 2013-02-08 | 2018-07-10 | 노파르티스 아게 | 항-il-17a 항체 및 자가면역 및 염증성 장애의 치료에서의 그의 용도 |
| MA42032A (fr) | 2015-02-02 | 2018-03-14 | Forma Therapeutics Inc | Acides 3-aryl-4-amido-bicyclo [4,5,0]hydroxamiques en tant qu'inhibiteurs de hdac |
| MX2021006421A (es) | 2018-12-19 | 2021-08-16 | Leo Pharma As | Anilidas de aminoácidos como moduladores de moléculas pequeñas de interleucinas-17 (il-17). |
-
2021
- 2021-10-25 UY UY0001039484A patent/UY39484A/es unknown
- 2021-10-29 AR ARP210103016A patent/AR123962A1/es unknown
- 2021-11-01 EP EP21801650.9A patent/EP4237417A1/en active Pending
- 2021-11-01 PE PE2023001510A patent/PE20231047A1/es unknown
- 2021-11-01 MX MX2023005076A patent/MX2023005076A/es unknown
- 2021-11-01 IL IL302447A patent/IL302447A/en unknown
- 2021-11-01 TW TW110140649A patent/TW202227408A/zh unknown
- 2021-11-01 KR KR1020237016828A patent/KR20230091945A/ko active Search and Examination
- 2021-11-01 CR CR20230180A patent/CR20230180A/es unknown
- 2021-11-01 CA CA3190738A patent/CA3190738A1/en active Pending
- 2021-11-01 WO PCT/IB2021/060092 patent/WO2022091056A1/en active Application Filing
- 2021-11-01 JP JP2023526268A patent/JP2023547470A/ja active Pending
- 2021-11-01 AU AU2021368247A patent/AU2021368247B2/en active Active
- 2021-11-01 US US18/033,100 patent/US20230391782A1/en active Pending
- 2021-11-01 CN CN202180067298.6A patent/CN116323596A/zh active Pending
-
2023
- 2023-04-26 DO DO2023000081A patent/DOP2023000081A/es unknown
- 2023-04-26 CO CONC2023/0005280A patent/CO2023005280A2/es unknown
- 2023-04-26 EC ECSENADI202330375A patent/ECSP23030375A/es unknown
- 2023-04-27 CL CL2023001220A patent/CL2023001220A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DOP2023000081A (es) | 2023-06-15 |
| JP2023547470A (ja) | 2023-11-10 |
| KR20230091945A (ko) | 2023-06-23 |
| AU2021368247A9 (en) | 2023-10-05 |
| MX2023005076A (es) | 2023-05-16 |
| CA3190738A1 (en) | 2022-05-05 |
| UY39484A (es) | 2022-06-30 |
| CR20230180A (es) | 2023-05-25 |
| AU2021368247B2 (en) | 2023-10-05 |
| TW202227408A (zh) | 2022-07-16 |
| IL302447A (en) | 2023-06-01 |
| CN116323596A (zh) | 2023-06-23 |
| CO2023005280A2 (es) | 2023-05-19 |
| CL2023001220A1 (es) | 2023-12-22 |
| AU2021368247A1 (en) | 2023-05-18 |
| PE20231047A1 (es) | 2023-07-11 |
| ECSP23030375A (es) | 2023-05-31 |
| US20230391782A1 (en) | 2023-12-07 |
| EP4237417A1 (en) | 2023-09-06 |
| WO2022091056A1 (en) | 2022-05-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR123962A1 (es) | Inhibidores de interleucina-17 | |
| AR114254A1 (es) | Moduladores del regulador de conductancia transmembrana de fibrosis quística, composiciones farmacéuticas, métodos de tratamiento y proceso de preparación de los moduladores | |
| AR119731A1 (es) | Inhibidores del inflamasoma nlrp3 | |
| AR107714A1 (es) | Derivados de pirazolo[1,5-a]pirazin-4-ilo | |
| AR117616A1 (es) | Compuestos anti-vih | |
| AR110139A1 (es) | COMPUESTOS MONO Y ESPIROCÍCLICOS QUE CONTIENEN CICLOBUTANO Y AZETIDINA COMO INHIBIDORES DE LA INTEGRINA aV | |
| AR110922A1 (es) | Compuestos inhibidores del vih | |
| AR118374A1 (es) | Inhibidores de la proteína tirosina fosfatasa y métodos para usarlos | |
| AR110153A1 (es) | ÁCIDOS PROPIÓNICOS 3-SUSTITUIDOS COMO INHIBIDORES DE LA INTEGRINA aV | |
| AR087052A1 (es) | Derivados de amina ciclica como antagonistas del receptor ep4 | |
| AR111808A1 (es) | Derivados de pirimidina como moduladores del receptor de pge2 | |
| AR089143A1 (es) | Triazolopiridinas sustituidas con actividad inhibidora de ttk | |
| AR116114A1 (es) | Amidas heterocíclicas de entre 5 y 7 miembros como inhibidores de jak | |
| AR109437A1 (es) | Derivados de n-(piridin-2-il)piridina-sulfonamida y su uso en el tratamiento de enfermedades | |
| AR096846A1 (es) | Dihidroquinoxalinonas y dihidropiridopirazinonas modificadas como inhibidores de la proteína bet | |
| AR116424A1 (es) | Moduladores de la somatostatina y usos de los mismos | |
| AR111874A1 (es) | Derivados de pirimidina | |
| AR094497A1 (es) | Compuestos tetracíclicos sustituidos con tiofeno y métodos de uso de los mismos para el tratamiento de enfermedades víricas | |
| AR100440A1 (es) | Derivados de carboxamida como inhibidores selectivos de smurf1 | |
| AR116022A1 (es) | Compuestos heteroaromáticos como inhibidores de vanina | |
| AR114564A1 (es) | DERIVADOS DE 2,4,6,7-TETRAHIDRO-PIRAZOLO[3,4-D]PIRIMIDIN-ONA COMO MODULADORES DEL RECEPTOR C5a Y COMPOSICIÓN FARMACÉUTICA QUE LOS COMPRENDE | |
| AR126351A1 (es) | Compuestos y sus sales inhibidores del inflamasoma nlrp3 | |
| AR120169A1 (es) | Derivados de 2-azaespiro[3.4]octano como agonistas de m4 | |
| AR091534A1 (es) | Derivados de sulfonamida y metodos de uso de los mismos para mejorar la farmacocinetica de un farmaco | |
| AR126733A1 (es) | Inhibidores de nicotinamida ripk1 |